Immunohistochemical Evaluation of Ovarian Hormonal Receptors in Canine Mammary Tumors


Background: In female dogs, ovarian hormones have a crucial role in the pathogenesis of mammary tumors. Ovarian hormones interact with nuclear receptors, estrogen receptor α (ERα) and β (ERβ), progesteron receptor (PR) and androgen receptor (AR) respectively. The aim of this study was to verify the existence of correlations between biological behaviour and immunohistochemical expression of estrogen receptor α (ERα) and β (ERβ), progesterone receptor (PR) and androgen receptor (AR) in canine mammary tumors. A total of sixty-four tumors were examined. Results: The expression of every receptor was higher in normal tissue and benign tumors than in malignant neoplasm. Among malignancies, the lowest levels of every receptor were detected in high grade carcinomas (p < 0.01). Lower levels of ERα and PR were associated with regional (p < 0.01) and/or distant (p < 0.05) metastasis. A lower expression of ERβ was found in carcinomas with nodal positive status (p < 0.05). High level of AR seemed weakly associated with the development of distant metastasis (p > 0.05). Conclusions: The expression of ERα and/or PR showed the positive prognostic value for the Spearman’s rank test (p < 0.01). ERβ also displayed a positive prognostic significance (p < 0.05). The levels of AR were inversely correlated only with grading of a slight positive correlation with metastatic power of carcinoma (p > 0.05). In human breast carcinoma, AR seems to be involved in metastatic development by up-regulation of metalloprotease of matrix (MMP). Therefore, evaluating the correlation among the presence of AR, expression of MMP and appearance of distant metastasis also in canine mammary tumors could be very interesting.

Share and Cite:

F. Mariotti, R. Giacomo and M. Subeide, "Immunohistochemical Evaluation of Ovarian Hormonal Receptors in Canine Mammary Tumors," Open Journal of Veterinary Medicine, Vol. 3 No. 2, 2013, pp. 104-110. doi: 10.4236/ojvm.2013.32017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] H. Elling and F. R. Ungemach, “Simultaneous Occurrence of Receptors for Estradiol, Progesterone and Dihydrotestosterone in Canine Mammary Tumors,” Journal of Cancer Research and Clinical Oncology, Vol. 105, No. 3, 1983, pp. 231-237. doi:10.1007/BF00395750
[2] A. L. Parodi, J. P. Mialot and P. M. Martin, “Canine and Feline Mammary Cancers as Animal Models for Hormone-Dependent Human Breast Tumors: Relationships between Steroid Receptor Profiles and Survival Rates,” Prognosis Cancer Res Ther, Vol. 31, 1984, pp. 357-365.
[3] G. R. Rutteman, “Hormones and Mammary Tumor Disease in Femal Dog: An Update,” In Vivo, Vol. 4, No. 1, 1990, pp. 33-40.
[4] W. Misdorp, “Canine Mammary Tumors: Protective Effect of Late Ovariectomy and Stimulating Effect of Progestins,” Veterinary Quarterly, Vol. 10, No 1, 1988, pp. 26-33. doi:10.1080/01652176.1988.9694142
[5] G. R. Rutteman and W. Misdorp, “Hormonal Background of Canine and Feline Mammary Tumors,” Journal of Reproduction and Fertility. Supplement, Vol. 47, 1993, pp. 483-487.
[6] D. C. Allred, J. M. Harvey, M. Berardo and G. M. Clark, “Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis,” Modern Pathology, Vol. 11, No. 2, 1998, pp. 155-168.
[7] C. K. Osborne, “Steroid Hormone Receptors in Breast Cancer Management,” Breast Cancer Research and Treatment, Vol. 51, No. 3, 1998, pp. 227-238. doi:10.1023/A:1006132427948
[8] H. Yamashita, Y. Ando, M. Nishio, Z. Zhang, M. Hamaguchi, K. Mita, S. Kobayashi, Y. Fujii and H. Iwase, “Immunohistochemical Evaluation of Hormone Receptor Status for Pedicting Response to Endocrine Therapy in Metastatic Breast Cancer,” Breast Cancer, Vol. 13, No. 1, 2006, pp. 74-83. doi:10.2325/jbcs.13.74
[9] A. Nieto, L. Pena, M. D. Perez-Alenza, M. A. Sanchez, J. M. Flores and M. Castano, “Immunohistologic Detection of Estrogen Receptor Alpha in Canine Mammary Tumors: Clinical and Pathologic Associations and Prognostic Significance,” Veterinary Pathology, Vol. 37, No. 3, 2000, pp. 239-247. doi:10.1354/vp.37-3-239
[10] G. R. Rutteman, W. Misdorp, M. A. Blankstein and W. E. Van den Brom, “Estrogen (ER) and Progestin Receptors (PR) in Mammary Tissue of the Female Dog: Different Receptor Profile in Non-Malignant and Malignant Stages,” British Journal of Cancer, Vol. 58, 1998, pp. 594-599.
[11] E. A. Sartin, S. Barnes, M. Toivio-Kinnucan, J. C. Wright and L. G. Wolfe, “Estrogen and Progesterone Receptor Status in Mammary Carcinomas and Correlation with Clinical Outcome in Dogs,” American Journal of Veterinary Research, Vol. 53, 1992, pp. 2196-2200.
[12] J. Martin de la Mulas, Y. Millan and R. Dios, “A Prospective Analysis of Immunohistochemically Determined Estrogen Receptor α and Progesterone Receptor Expression and Host and Tumor Factors as Predictors of Disease-Free Period in Mammary Tumors of the Dog,” Veterinary Pathology, Vol. 42, No. 2, 2005, pp. 200-212. doi:10.1354/vp.42-2-200
[13] F. Millanta, M. Calandrella, G. Bari, M. Niccolini, I. Vannozzi and A. Poli, “Comparison of Steroid Receptor Expression in Normal Dysplastic and Neoplastic Canine and Feline Mammary Tissues,” Research in Veterinary Science, Vol. 79, No. 3, 2005, pp. 225-232. doi:10.1016/j.rvsc.2005.02.002
[14] H. Boldizsar, T. Muray, I. Szamel, O. Szenci and J. Csenki, “Studies on Canine Mammary Tumors II. Oestradiol and Progesterone Receptor Binding Capacity and Histological Type,” Acta Veterinaria Hungarica, Vol. 40, No. 1-2, 1992, pp. 89-97.
[15] I. Donnay, J. Rauis, N. Devieeschouer, P. Wonters-Ballman, G. Leclerq and J. Verstegen, “Comparison of Estrogen and Progesterone Receptor Expression in Normal and Tumoral Mammary Tissue from Dog,” American Journal of Veterinary Research, Vol. 56, No. 9, 1995, pp. 1118-1194.
[16] J. P. Mialot, F. André, P. M. Martin, D. M. Cotard and J. P. Raynaud, “Etude de Récepteurs des Hormones Steroids dans les Tumours Mammaries de la Chienne II. Corrélations Avec Quelques Caractéristiques Cliniques,” Rec Med Vet, Vol. 158, 1982, pp. 513-521.
[17] J. Martin de la Mulas, J. Ordas, M. Y. Millan, F. Chacon, M. De Lara, A. Espinosa de los Monteros, C. Reymundo and A. Jover, “Immunohistochemical Expression of Estrogen Receptor β in Normal and Tumoral Canine Mammary Gland,” Veterinary Pathology, Vol. 41, No. 3, 2004, pp. 269-272. doi:10.1354/vp.41-3-269
[18] J. V. Illera, M. D. Perez-Alenza, A. Nieto, M. A. Jimenez, G. Silvan, S. Dunner and L. Pena, “Steroid and Receptors in Canine Mammary Cancer,” Steroids, Vol. 71, No. 7, 2006, pp. 541-548. doi:10.1016/j.steroids.2005.11.007
[19] J. Thuroczy, G. J. K. Reisvaag, E. Perge, A. Tibold, J. Szilagyi and L. Balogh, “Immunohistochemical Detection of Progesterone and Cellular Proliferation in Canine Mammary Tumors,”Journal of Comparative Pathology, Vol. 137, No. 2-3, 2007, pp. 122-129. doi:10.1016/j.jcpa.2007.05.005
[20] L. N. Owen, “TNM Classification of Tumors in Domestic Animals,” World Health Organization, Geneve, 1980.
[21] W. Misdorp, R. W. Else, E. Hellmen and T. P. Lipscomb, “Histological Classification of Mammary Tumors of the Dog and Cat. Second Series,” Vol. 7, Armed Forces Insitute of Pathology and World Health Organization, Washington, 1999.
[22] I. D. Kurzman and S. Gilbertson, “Prognostic Factors in Canine Mammary Tumors,” Seminars in Veterinary Medicine and Surgery (Small Animal), Vol. 1, 1986, pp. 25-32.
[23] L. S. Lantinga-van Leewen, E. van Garderen, G. R. Rutteman and J. A. Mol, “Cloning and Cellular Localization of the Canine Progesterone Recepor: Co-Localization with Growth Hormone in the Mammary Gland,” The Journal of Steroid Biochemistry and Molecular Biology, Vol. 75, No. 4-5, 2000, pp. 219-228. doi:10.1016/S0960-0760(00)00173-4
[24] D. R. J. Snead, J. A. Bell, A. R. Dixon, R. I. Nicholson, C. W. Elston, R. W. Blamey and O. Ellis, “Methodology of Immunohistological Detection of Estrogen Receptor in Human Breast Carcinoma in Formalin-Fixed Paraffin-Embeeded Tissue: A Comparison with Frozen Section Methodology,” Histopathology, Vol. 23, No. 3, 1993, pp. 233-238. doi:10.1111/j.1365-2559.1993.tb01195.x
[25] P. Tosi, P. A. Baak and P. Luzi, “Correlation between Immunohistochemically Determined Estrogen Receptor Content Using Monoclonal Antibodies, and Qualitative and Quantitative Features in Ductal Breast Carcinoma,” Histopathology, Vol. 11, No. 7, 1987, pp. 741-751. doi:10.1111/j.1365-2559.1987.tb02688.x
[26] L. O. Gonzales, M. D. Corte, J. Vazquez, S. Junquera, R. Sanchez, A. C. Alvarez, J. C. Rodriguez, M. L. Lamelas and F. J. Vizoso, “Androgen Receptor in Breast Cancer: Relationship with Clinicopathological Characteristics of the Tumors, Prognosis and Expression of Metalloproteases and Their Inhibitors,” BMC Cancer, Vol. 8, 2008, p. 149. doi:10.1186/1471-2407-8-149

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.